Pharma
Novo becomes second ever European firm to breach $500bn market value
Novo Nordisk shares have gained 60 per cent in the past year, fuelled by surging demand for Ozempic and Wegovy
Novo Nordisk shares have gained 60 per cent in the past year, fuelled by surging demand for Ozempic and Wegovy